1Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation: challenging the status quo [J]. Clin Transplant,2007,21 (2) : 149-158.
2Avery RK. Update in management of ganciclovirre-sistant Cytomegalovirus infection [ J ] . Curr Opin Infect Dis,2008,21 (4) :433-437.
3Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients [J]. Antimicrob Agents Chemother,2000, 44 (10) :2811-2815.
4Jabs DA, Martin BK, Forman MS, et al. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and Cytomegalovirus retinitis: the Cytomegalovirus and viral resistance study group report number 8 [ J ]. Am J Ophthalmol,2001, 132 (5) : 700- 710.
5Chou S, Van Wechel LC, Lichy HM, et al. Phenotyping of Cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene [ J ]. Antimicrob Agents Chemother, 2005,49 (7) : 2710-2715.
6Chou S, Lurain NS, Thompson KD, et al. Viral DNA polymerase mutations associated with drug resistance in Human cytomegalovirus [ J ]. J Infect Dis, 2003, 188(1): 32-39.
7Mousavi-Jazi M,Schloss L,Wahren B, et al. Point mu-tations induced by foscarnet (PFA) in the Human cytomegalovirus DNA polymerase [ J ]. J Clin Virol,2003, 26(3) :301-306.
8Gilbert C,Boivin G. Human cytomegalovirus resistance to antiviral drugs[ J]. Antimicrob Agents Chemother, 2005, 49(3) :873-883.
9Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious Cytomegalovirus infection[ J]. J Infect Dis, 1991, 163(4) :716-719.
10Lurain NS, Bhorade SM, Pursell K J, et al. Analysis and characterization of antiviral drug-resistant Cyto-rnegalovirus isolates from solid organ transplant recipients[J]. J Infect Dis,2002,186(6) :760-768.
